Boryung announced that it has started supplying the anticancer drug Alimta (active ingredient: pemetrexed) to Taiwan's Lotus Pharmaceutical, marking the expansion of its global contract development and manufacturing organization (CDMO) business.
This supply marks the first instance of Boryung's global CDMO operations becoming fully operational. Following the signing of a CDMO contract with Lotus in 2024, Boryung completed quality verification and regulatory procedures before commencing the first supply from its Yesan campus.
Boryung's pharmaceutical production facility at the Yesan campus is a smart factory covering 145,097 square meters dedicated to CDMO production. Since its completion in 2019, it has demonstrated global-level production capabilities by obtaining European Union Good Manufacturing Practice (EU-GMP) certification in 2023. The company plans to accelerate the expansion of its global supply of cytotoxic anticancer drugs and its CDMO business.
Recently, a shortage of cytotoxic anticancer drugs has become a pressing issue in the global market. Disruptions at major production sites and instability in the supply of active pharmaceutical ingredients have led to shortages of essential anticancer medications, highlighting the importance of securing stable supply chains.
Since acquiring Gemza in 2020, Boryung has expanded its portfolio of original anticancer drugs, including Alimta. Last year, it strengthened its anticancer drug portfolio by acquiring the domestic and global business rights for Taxotere. The company emphasizes its advantage in internalizing the production technology of original products within its own facilities.
After acquiring the domestic business for Alimta, Boryung has improved the product's competitiveness and profitability by transitioning from a powder formulation to a liquid formulation. The company plans to apply its experience in internalizing production technology and formulation improvement to enhance its competitiveness in the global CDMO market.
Kim Sung-jin, Boryung's Chief Strategy Officer (CSO), stated, "The importance of stability in pharmaceutical supply and quality management capabilities is growing in the global market. Based on our global-level production infrastructure and technology, we aim to establish ourselves as a trusted supply partner."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.